Ampicillin

Lyfius Pharma Pvt Ltd, a manufacturer of penicillin G, announced the launch of its state-of-the-art manufacturing facility in Kakinada, Andhra Pradesh, on October 29th.  The company has invested 25 billion rupees in the plant, which has an annual production capacity of 15,000 tons, under the Production Linked Incentive (PLI) scheme. The facility was inaugurated online by Prime Minister Narendra Modi, with the presence of several Indian ministers, including Chemicals and Fertilizers Minister Jagat Prakash Nadda, Labour and Employment Minister Mansukh Mandaviya, and others.  Lyfius Pharma's director, MV Rama Krishna, highlighted the significance of the Pen-G factory's launch as a milestone in strengthening local production and reducing reliance on imported key drug components.  The investment underscores the company's commitment to the government's vision of "Atmanirbhar Bharat" (Self-Reliant India), aiming to establish India as a global pharmaceutical manufacturing hub. The company expects commercial production to accelerate in the fiscal year 2025, enhancing domestic output of key starting materials (KSM), drug intermediates (DI), and active pharmaceutical ingredients (API).  Lyfius Pharma, a subsidiary of Aurobindo Pharma, operates the advanced facility in Andhra Pradesh, which is one of India's largest fermentation-based antibiotic intermediate plants, featuring large-capacity fermenters and automated starch and glucose plants. The project feasibility report outlines the production of 2,000 tons/year of 7-ACA, 15,000 tons/year of penicillin G, 198,000 tons/year of glucose, and 4,200 tons/year of 6-APA, with co-line products including 1,800 tons/year of amoxicillin trihydrate (enzyme method) and 1,800 tons/year of ampicillin trihydrate (enzyme method). Aurobindo Pharma's Q2FY2025 financial results show an 8.0% year-over-year increase in revenue to 77.96 billion rupees, with an EBITDA of 19.54 billion rupees before research and development, a profit margin of 25.1%, and a net profit of 8.17 billion rupees, up 8.6%.  The company's performance indicates positive growth trends, particularly in Europe and growth markets, despite a 22.8% decline in ARV (antiretroviral) business revenue.  The API business maintained stable revenue at 11.56 billion rupees, contributing 14.8% to total revenue.

According to the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening conditions due to resistant bacterial infections each year. MRX-8 not only shows excellent safety and tolerability but also demonstrates strong antibacterial activity against multidrug-resistant Gram-negative. Bacteria ("MDR-GNB"), indicating significant clinical application potential. In China, the total number of days of antibiotic treatment for MDR-GNB infections increased from 43 million days in 2018 to 68.4 million days in 2023, with a compound annual growth rate of 10.3% during this period. SHANGHAI, June 6, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) successfully completed the Phase I clinical trial of its self-developed new injectable polymyxin antibacterial drug MRX-8 in China, achieving the expected goals. MRX-8 is primarily used to treat infections caused by multidrug-resistant Gram-negative bacteria. This significant milestone marks a crucial step towards MRX-8 becoming a safe and effective new antibacterial drug. China Phase I Clinical Trial Results The Phase I clinical trial in China was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetic characteristics of MRX-8 in healthy Chinese subjects. The trial included single ascending dose and multiple ascending dose components, demonstrating that MRX-8's drug exposure in the human body increases proportionally with the dose. The study demonstrated that at the expected clinical dose of 2.5 mg/kg once daily, MRX-8 can achieve ideal therapeutic effects against infections caused by multidrug-resistant Gram-negative bacteria. Moreover, MRX-8 exhibited good safety in healthy Chinese adults. Throughout the study, no subjects withdrew or terminated the trial due to adverse events, and no CTCAE Grade 3 or higher adverse events occurred. The most common adverse events were mild sensory reduction and decreased glomerular filtration rate, all of which were CTCAE Grade 1 and resolved without intervention. Only two subjects in the multiple dose group experienced CTCAE Grade 2 adverse events, both of which were injection site reactions.. The Study's Impact and Future Plans As one of the company's important new drug development product pipelines, the successful completion of the Phase I clinical trial of MRX-8 in China is of great significance. The study results indicate that MRX-8 exhibits good safety in healthy Chinese adults at the expected clinical dose, laying a solid foundation for its future clinical use. The success of this clinical trial not only provides strong data support for subsequent clinical development, but also enhances confidence in its future application in treating multidrug-resistant Gram-negative bacterial infections. This marks a crucial step forward for MRX-8 in becoming a safe and effective new antibacterial drug. The company will combine the results and data from both the US and China Phase I clinical trials to formulate the next steps in MRX-8's clinical development plan. The company will actively explore development pathways for different potential indications, aiming to make MRX-8 a new antibacterial drug with significant clinical value for treating multidrug-resistant Gram-negative bacterial infections, in order to meet the rapidly growing need for clinical treatment. The company is committed to creating maximum value for society and the company, driving MRX-8 towards market availability, and providing new hope for patients. About MRX-8 MRX-8 is a novel injectable polymyxin antibacterial drug independently developed by MicuRx Pharmaceuticals, primarily used to treat severe infections caused by multidrug-resistant Gram-negative bacteria. Traditional polymyxin drugs have limited clinical use due to their high risk of nephrotoxicity and neurotoxicity. MRX-8, through meticulous structural design, not only maintains or improves therapeutic efficacy, but also significantly reduces these toxic risks. Results from the Phase I clinical trial completed in the United States in 2022 showed that MRX-8 achieves ideal therapeutic effects against infections caused by multidrug-resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. Multidrug-Resistant Gram-Negative Bacteria and Market Demand Gram-negative bacteria are resistant to multiple drugs and are increasingly resistant to most available antibiotics. Multidrug-resistant Gram-negative bacteria (MDR-GNB) are a specific class of Gram-negative bacteria whose multidrug resistance is defined as resistance to three or more commonly prescribed antibiotics (ceftazidime, ciprofloxacin, meropenem, gentamicin, ampicillin/sulbactam, or piperacillin/tazobactam). Infections caused by MDR-GNB have a mortality rate five times higher than infections caused by conventional Gram-negative bacteria. Globally, infections caused by multidrug-resistant Gram-negative bacteria have become a major public health challenge. According to the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening conditions due to resistant bacterial infections each year. In hospitals and intensive care units, infections caused by resistant Gram-negative bacteria result in high mortality rates and significant treatment costs, posing substantial pressure on healthcare systems. In China, the total number of days of antibiotic treatment for MDR-GNB infections increased from 43 million days in 2018 to 68.4 million days in 2023, with a compound annual growth rate of 10.3%.[1] Currently, the market has limited options for effectively treating multidrug-resistant Gram-negative bacterial infections, and the severe side effects of traditional polymyxin drugs further restrict their clinical use. The development and clinical trial results of MRX-8 address this unmet market need. MRX-8 not only shows excellent safety and tolerability but also demonstrates strong antibacterial activity against multidrug-resistant Gram-negative bacteria, indicating significant clinical application potential. [1] Data source: Frost & Sullivan Analysis View original content: SOURCE MicuRx Pharmaceuticals